Drug Profile

Isothiafludine

Alternative Names: NZ-4; W28; W28F

Latest Information Update: 21 Apr 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shanghai Institute of Materia Medica
Developer ShangHai HaiHe Pharmaceutical
Class Amides; Antivirals; Fluorobenzenes; Small molecules; Thiazoles
Mechanism of Action Hepatitis B virus replication inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Hepatitis B

Most Recent Events

21 Apr 2022 Discontinued - Phase-I for Hepatitis B (In volunteers) in China (PO) (Haihe Biopharma pipeline, April 2022)
28 May 2018 No recent reports of development identified for phase-I development in Hepatitis-B(In volunteers) in China (PO, Capsule)
10 May 2016 Chemical structure information added

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com